TransCode Therapeutics, Inc. (RNAZ)
NasdaqCM
Price as at 1 Oct 2026, 00:42 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
TransCode Therapeutics, Inc. trades at $1.68. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; and TTX-siMYC, an siRNA-based MYC inhibitor. The company is also developing oncolytic virus therapy. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its RNAZ data?
Fundamentals for RNAZ come from company filings and exchange data, as listed on NasdaqCM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 00:42 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for RNAZ, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.